{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:42:10Z","timestamp":1782960130101,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41429-024-00738-y","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T09:02:00Z","timestamp":1716195720000},"page":"533-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antidermatophyte activity and PK\/PD of ME1111 in a guinea pig model of tinea corporis"],"prefix":"10.1038","volume":"77","author":[{"given":"Naomi","family":"Takei-Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nagira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Kubota-Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Chikada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Maebashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"738_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1067\/mjd.2000.107754","volume":"43","author":"MA Ghannoum","year":"2000","unstructured":"Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"738_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1067\/mjd.2000.104794","volume":"43","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians\u2019 offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43:244\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"738_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2133.1995.tb02741.x","volume":"133","author":"H Heikkil\u00e4","year":"1995","unstructured":"Heikkil\u00e4 H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133:699\u2013703.","journal-title":"Br J Dermatol"},{"key":"738_CR4","doi-asserted-by":"publisher","first-page":"e1004105","DOI":"10.1371\/journal.ppat.1004105","volume":"10","author":"M Ghannoum","year":"2014","unstructured":"Ghannoum M, Isham N. Fungal Nail Infections (Onychomycosis): A never-ending story? PLoS Pathog. 2014;10:e1004105.","journal-title":"PLoS Pathog"},{"key":"738_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","volume":"1","author":"BE Elewski","year":"2000","unstructured":"Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol. 2000;1:19\u201326.","journal-title":"Am J Clin Dermatol"},{"key":"738_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1517\/13543784.16.2.157","volume":"16","author":"MRK Alley","year":"2007","unstructured":"Alley MRK, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16:157\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"738_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1128\/AAC.01739-15","volume":"60","author":"Y Tabata","year":"2015","unstructured":"Tabata Y, Takei-Masuda N, Kubota, Takahata S, Ohyama M, Kaneda K, et al. Characterization of antifungal activity and nail penetration of ME1111, a new antifungal agent for topical treatment of onychomycosis. Antimicrob Agents Cheomother. 2015;60:1035\u20139.","journal-title":"Antimicrob Agents Cheomother"},{"key":"738_CR8","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1128\/AAC.00992-15","volume":"59","author":"M Ghannoum","year":"2015","unstructured":"Ghannoum M, Isham N, Long L. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes. Antimicrob Agents Chemother. 2015;59:5154\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR9","first-page":"e00779","volume":"62","author":"N Kubota-Ishida","year":"2017","unstructured":"Kubota-Ishida N, Takei-Masuda N, Kaneda K, Nagira Y, Chikada T, Nomoto M, et al. In vitro human onychopharmacokinetic and pharmacodynamic analyses of ME1111, a new topical agent for onychomycosis. Antimicrob Agents Chemother. 2017;62:e00779\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR10","unstructured":"Takei-Masuda N, Nagira Y, Kaneda K, Chikada T, Nomoto M, Tabata Y, et al. Potent antifungal activity of ME1111 against Trichophyton species in the presence of keratin [abstract F-742] 55th Intersci Conf Antimicrob Agents Chemother 2015."},{"key":"738_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev.biochem.72.121801.161700","volume":"72","author":"G Cecchini","year":"2003","unstructured":"Cecchini G. Function and structure of complex II of the respiratory chain. Annu Rev Biochem. 2003;72:77\u2013109.","journal-title":"Annu Rev Biochem"},{"key":"738_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1128\/AAC.01790-15","volume":"60","author":"S Takahata","year":"2016","unstructured":"Takahata S, Kubota N, Takei-Masuda N, Yamada T, Maeda M, Alshahmi MM, et al. Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis. Antimicrob Agents Chemother. 2016;60:873\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/03639045.2016.1201098","volume":"43","author":"X Hui","year":"2017","unstructured":"Hui X, Jung EC, Zhu H, Maibach H. Antifungal ME1111 in vitro human onychopharmacokinetics. Drug Dev Ind Pharm. 2017;43:22\u20139.","journal-title":"Drug Dev Ind Pharm"},{"key":"738_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(01)00989-9","volume":"236","author":"S Murdan","year":"2002","unstructured":"Murdan S. Drug delivery to the nail following topical application. Int J Pharm. 2002;236:1\u201326.","journal-title":"Int J Pharm"},{"key":"738_CR15","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1128\/AAC.00111-14","volume":"58","author":"K Sugiura","year":"2014","unstructured":"Sugiura K, Sugimoto N, Hosaka S, Katafuchi-Nagashima M, Arakawa Y, Tatsumi Y, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Cheomother. 2014;58:3837\u201342.","journal-title":"Antimicrob Agents Cheomother"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/jof1020107","volume":"1","author":"RA Pollak","year":"2015","unstructured":"Pollak RA, Siu WJJ, Tatsumi Y, Pillai R. Efinaconazole topical solution, 10%: factors contributing to onychomycosis success. J Fungi (Basel). 2015;1:107\u201314.","journal-title":"J Fungi (Basel)"},{"key":"738_CR17","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1128\/AAC.46.12.3797-3801.2002","volume":"46","author":"Y Tatsumi","year":"2002","unstructured":"Tatsumi Y, Yokoo M, Senda H, Kakehi K. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother. 2002;46:3797\u2013801.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3314\/mmj.20-00011","volume":"61","author":"N Hasegawa","year":"2020","unstructured":"Hasegawa N, Shibuya K. Development of an Animal Model of Onychomycosis in Guinea Pigs. Med Mycol J. 2020;61:55\u201360.","journal-title":"Med Mycol J"},{"key":"738_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/mmy\/myaa111","volume":"3","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Hirakawa S, Nagai H, Inagaki K. A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model. Med Mycol. 2021;3:289\u201395.","journal-title":"Med Mycol"},{"key":"738_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11046-022-00664-3","volume":"187","author":"A Masumoto","year":"2022","unstructured":"Masumoto A, Sugiura K, Matsuda Y, Tachibana H, Tatsumi Y. Evaluation of topical antifungals using a new predictive animal model for efficacy against severe tinea unguium: a comparison of efinaconazole and luliconazole. Mycopathologia. 2022;187:481\u20139.","journal-title":"Mycopathologia"},{"key":"738_CR21","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1128\/AAC.00399-11","volume":"55","author":"T Shimamura","year":"2011","unstructured":"Shimamura T, Kubota N, Nagasaka S, Suzuki T, Mukai H, Shibuya K. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents. Antimicrob Agents Chemother. 2011;55:3150\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR22","first-page":"609","volume":"14","author":"D Coronado","year":"2015","unstructured":"Coronado D, Merchant T, Chanda S, Zane LT. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical. J Drugs Dermatol. 2015;14:609\u201314.","journal-title":"J Drugs Dermatol"},{"key":"738_CR23","doi-asserted-by":"publisher","first-page":"e0159661","DOI":"10.1371\/journal.pone.0159661","volume":"11","author":"Y Matsuda","year":"2016","unstructured":"Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y, Tatsumi Y. Efficacy coefficients determined using nail permeability and antifungal activity in keratin-containing media are useful for predicting clinical efficacies of topical drugs for onychomycosis. PLoS One. 2016;11:e0159661.","journal-title":"PLoS One"},{"key":"738_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.clindermatol.2010.03.037","volume":"28","author":"MW Cashman","year":"2010","unstructured":"Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28:420\u20135.","journal-title":"Clin Dermatol"},{"key":"738_CR25","unstructured":"Winckle G, Fieldson GT Compositions and methods for treating diseases of the nail. United states patent application publication. US 2014\/0228403 A1."},{"key":"738_CR26","unstructured":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, 2nd ed. approved standard. (M38-A2) Wayne PA: Clinical and Laboratory Standards Institute; 2008."},{"key":"738_CR27","first-page":"150","volume":"48","author":"Y Niwano","year":"1995","unstructured":"Niwano Y, Tabuchi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. Therapeutic efficacy of lanoconazole ointment in guinea pig model of tinea corporis, a comparative study with ointment and cream preparations. Jpn J Antibiot. 1995;48:150\u20134.","journal-title":"Jpn J Antibiot"},{"key":"738_CR28","first-page":"a019653","volume":"55","author":"AJ Lepak","year":"2014","unstructured":"Lepak AJ, Andes DR. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med. 2014;55:a019653.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"738_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1128\/AAC.01573-12","volume":"57","author":"A Elefanti","year":"2013","unstructured":"Elefanti A, Mouton JW, Krompa K, Al-Saigh R, Verweij PE, Zerva L, et al. Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob Agents Chemother. 2013;57:1625\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01187-21","volume":"66","author":"C Pressiat","year":"2022","unstructured":"Pressiat C, Ait-Ammar N, Daniel M, Hulin A, Botterel F, Levesque E. Pharmacokinetics\/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients. Antimicrob Agents Chemother. 2022;66:e0118721.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1254\/fpj.125.291","volume":"125","author":"S Sobue","year":"2005","unstructured":"Sobue S, Sekiguchi K, Nabeshima T. The pharmacokinetics of oral antifungal drugs and their efficacy against cutaneous mycosis. Nihon Yakurigaku Zasshi. 2005;125:291\u20135.","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"738_CR32","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1128\/AAC.03073-15","volume":"60","author":"L Long","year":"2016","unstructured":"Long L, Hager C, Ghannoum M. Evaluation of the efficacy of ME1111 in the topical treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother. 2016;60:2343\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"738_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3314\/jjmm.45.143","volume":"45","author":"S Watanabe","year":"2004","unstructured":"Watanabe S. Optimal dosages and cycles of itraconazole pulse therapy for onychomycosis. Jpn J Med Mycol 2004;45:143\u20137.","journal-title":"Jpn J Med Mycol"},{"key":"738_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jps.10003","volume":"91","author":"X Hui","year":"2002","unstructured":"Hui X, Shainhouse JZ, Tanojo H, Anigbogu A, Markus G, Maibach HI, et al. Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. J Pharm Sci. 2002;91:189\u201395.","journal-title":"J Pharm Sci"},{"key":"738_CR35","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/jps.20901","volume":"96","author":"X Hui","year":"2007","unstructured":"Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci. 2007;96:2622\u201331.","journal-title":"J Pharm Sci"},{"key":"738_CR36","first-page":"20","volume":"6","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Reece B, Smith K, Miller. Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. J Clin Aesthet Dermatol. 2013;6:20\u20134.","journal-title":"J Clin Aesthet Dermatol"},{"key":"738_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","volume":"68","author":"BE Elewski","year":"2013","unstructured":"Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"738_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-2230.1989.tb00903.x","volume":"14","author":"H Yamaguchi","year":"1989","unstructured":"Yamaguchi H, Uchida K. Once daily administration of terbinafine to guinea-pigs with experimental dermatophytosis. Clin Exp Dermatol. 1989;14:108\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"738_CR39","first-page":"1076","volume":"20","author":"SR Lipner","year":"2021","unstructured":"Lipner SR, Joseph WS, Vlahovic TC, Scher RK, Rich P, Ghannoum M, et al. Therapeutic recommendations for the treatment of toenail onychomycosis in the US. J Drugs Dermatol. 2021;20:1076\u201384.","journal-title":"J Drugs Dermatol"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00738-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T23:02:04Z","timestamp":1722207724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1038\/s41429-024-00738-y","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"3 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are employees of Meiji Seika Pharma Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}